Capricor Therapeutics, Inc. - Common Stock (CAPR)
12.22
+0.61 (5.25%)
Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases
The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine.
